Incidence and risk factors for development of cardiac toxicity in adult patients with newly diagnosed acute myeloid leukemia
Preprint
- 27 December 2022
- preprint
- Published by Springer Nature in Research Square
Abstract
The incidence of cardiac morbi-mortality in acute myeloid leukemia (AML) is not well known. We aim to estimate the cumulative incidence (CI) of cardiac events in AML patients (pts) and to identify risk factors for their occurrence. Among 571 newly diagnosed AML pts, 26 (4.6%) developed fatal cardiac events and 19 (3.6%) among 525 treated pts (CI: 2% at 6 months; 6.7% at 9 years). Prior heart disease was associated with development of fatal cardiac events [Hazard Ratio (HR) = 1.9]. The CI of non-fatal cardiac events was 43.7% at 6 months and 56.9% at 9 years. Age ≥ 65 (HR = 2.2), relevant cardiac antecedents (HR = 1.4) and non-intensive chemotherapy (HR = 1.8) were associated with non-fatal cardiac events. The 9-years CI of grade 1–2 QTcF prolongation was 11.2%, grade 3 was 2.7%, and no patient had grade 4–5 event. The 9-years CI of grade 1–2 cardiac failure was 1.3%, grade 3–4 was 15%, and grade 5 2.1%; of grade 1–2 arrhythmia was 1.9%, grade 3–4 was 9.1%, and grade 5 1%. Among 285 intensive therapy pts, median overall survival decreased in those experiencing grade 3–4 cardiac events (p < 0.001). We observed a high incidence of cardiac toxicity associated with significant mortality in AML.Keywords
All Related Versions
This publication has 18 references indexed in Scilit:
- Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Children’s Oncology GroupJournal of Clinical Oncology, 2019
- Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugsCancer Treatment Reviews, 2018
- FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future DirectionsMolecular Cancer Therapeutics, 2017
- 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice GuidelinesEuropean Heart Journal, 2016
- Prevalence, Management, and Clinical Consequences of QT Interval Prolongation During Treatment With Arsenic TrioxideJournal of Clinical Oncology, 2014
- Cardio-oncology in Targeting the Her Receptor Family: the Puzzle of Different Cardiotoxicities of HER2 InhibitorsFuture Cardiology, 2011
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNetBlood, 2010
- Congestive heart failure in patients treated with doxorubicinCancer, 2003
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia.Journal of Clinical Oncology, 1995